Spots Global Cancer Trial Database for locally advanced solid tumor
Every month we try and update this database with for locally advanced solid tumor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) | NCT06415487 | Locally Advance... Metastatic Soli... | Cyclophosphamid... Fludarabine ACE2016 Pembrolizumab | 18 Years - | Acepodia Biotech, Inc. | |
| A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab | NCT05378425 | Cancer Tumor, Solid Advanced Solid ... Metastatic Canc... Locally Advance... | NTX-1088 Pembrolizumab | 18 Years - | Nectin Therapeutics Ltd | |
| The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors | NCT04614740 | Locally Advance... Metastatic Soli... | VC004 | 18 Years - | Jiangsu vcare pharmaceutical technology co., LTD | |
| IBI3001 in Participants With Unresectable, Locally Advanced or Metastatic Solid Tumors | NCT06349408 | Locally Advance... | IBI3001 | 18 Years - | Innovent Biologics (Suzhou) Co. Ltd. | |
| Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | NCT03881488 | Locally Advance... Metastatic Canc... Non-small Cell ... Small Cell Lung... Mesothelioma Melanoma Head and Neck C... | CTX-471 Pembrolizumab (... | 18 Years - | Compass Therapeutics | |
| A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers | NCT04260802 | Cancer Neoplasms Metastatic Canc... Triple Negative... Gastric Cancer Cervical Cancer Ovarian Cancer Hepatocellular ... Squamous Cell C... Urothelial Carc... Urothelial Neop... Non Small Cell ... Renal Cell Carc... Locally Advance... Locally Advance... Squamous Cell C... Sarcoma Merkel Cell Car... Bladder Cancer | OC-001 OC-001 in Combi... | 18 Years - | Ocellaris Pharma, Inc. | |
| ACE2016 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors Expressing Epidermal Growth Factor Receptor (EGFR) | NCT06415487 | Locally Advance... Metastatic Soli... | Cyclophosphamid... Fludarabine ACE2016 Pembrolizumab | 18 Years - | Acepodia Biotech, Inc. | |
| A Phase 1 Study to Assess the Effect of Hepatic Impairment on the Pharmacokinetics of Repotrectinib in Advanced Cancer Patients | NCT05828277 | Locally Advance... Metastatic Soli... | repotrectinib (... | 18 Years - | Turning Point Therapeutics, Inc. | |
| A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | NCT05731271 | Locally Advance... Metastatic Tumo... Colorectal Aden... | TST003 | 18 Years - | Suzhou Transcenta Therapeutics Co., Ltd. | |
| A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib | NCT04814667 | Solid Tumor, Ad... Locally Advance... Metastatic Canc... | 25 Years - | Centre Leon Berard | ||
| ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | NCT04319757 | Locally Advance... Metastatic Canc... Solid Tumor HER2-positive G... HER2-positive M... | ACE1702 Cyclophosphamid... Fludarabine | 18 Years - | Acepodia Biotech, Inc. | |
| Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer | NCT04250948 | Gastric Cancer Locally Advance... | JS001 Oxaliplatin S1 Capecitabine | 18 Years - 75 Years | Sun Yat-sen University | |
| A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations | NCT05769075 | Locally Advance... Metastatic Soli... | TY-2136b TY-2136b | 18 Years - | TYK Medicines, Inc | |
| A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab | NCT05378425 | Cancer Tumor, Solid Advanced Solid ... Metastatic Canc... Locally Advance... | NTX-1088 Pembrolizumab | 18 Years - | Nectin Therapeutics Ltd | |
| Efficacy of Perioperative Chemotherapy Plus PD-1 Antibody in the Locally Advanced Gastric Cancer | NCT04250948 | Gastric Cancer Locally Advance... | JS001 Oxaliplatin S1 Capecitabine | 18 Years - 75 Years | Sun Yat-sen University | |
| QUILT-3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers | NCT04050709 | Locally Advance... Metastatic Canc... Solid Tumor | PD-L1 t-haNK | 18 Years - | ImmunityBio, Inc. | |
| Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients | NCT05002140 | Metastasis Locally Advance... Recurrent Cance... | XRD-0394 Palliative radi... | 18 Years - | XRad Therapeutics Inc | |
| A Study of NVL-655 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ALK Rearrangement or Activating ALK Mutation (ALKOVE-1) | NCT05384626 | Locally Advance... Metastatic Soli... | NVL-655 | 12 Years - | Nuvalent Inc. | |
| FOG-001 in Locally Advanced or Metastatic Solid Tumors | NCT05919264 | Cancer Colorectal Canc... Solid Tumor Locally Advance... Metastatic Canc... Gastric Cancer Non-small Cell ... Non-small Cell ... Non-small Cell ... Non-small Cell ... Non-Small Cell ... Gastroesophagea... WNT Pathway β-catenin Beta-catenin Adenomatous Pol... APC | FOG-001 FOG-001 | 18 Years - | Fog Pharmaceuticals, Inc. | |
| A Study of ES014 in Patients With Locally Advanced or Metastatic Solid Tumours | NCT05717348 | Solid Tumor Locally Advance... Metastatic Soli... | ES014 | 18 Years - | Elpiscience (Suzhou) Biopharma, Ltd. | |
| Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | NCT05919537 | Non-Small Cell ... Pancreatic Canc... Locally Advance... Metastatic Soli... | HMBD-001 Docetaxel Nab-paclitaxel Gemcitabine | 18 Years - | Hummingbird Bioscience | |
| A Study of CN202 in Adult Subjects With Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies | NCT05028478 | Locally Advance... Metastatic Soli... Hematologic Mal... | CN202 | 18 Years - | Curon Biopharmaceutical (Australia) Co Pty Ltd | |
| A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors | NCT05731271 | Locally Advance... Metastatic Tumo... Colorectal Aden... | TST003 | 18 Years - | Suzhou Transcenta Therapeutics Co., Ltd. | |
| Phase 1/2 Study of OBI-999 in Patients With Advanced Solid Tumors | NCT04084366 | Locally Advance... | OBI-999 OBI-999 | 18 Years - | OBI Pharma, Inc | |
| A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib | NCT04814667 | Solid Tumor, Ad... Locally Advance... Metastatic Canc... | 25 Years - | Centre Leon Berard | ||
| ACE1702 in Subjects With Advanced or Metastatic HER2-expressing Solid Tumors | NCT04319757 | Locally Advance... Metastatic Canc... Solid Tumor HER2-positive G... HER2-positive M... | ACE1702 Cyclophosphamid... Fludarabine | 18 Years - | Acepodia Biotech, Inc. | |
| A Study of MNRP1685A in Combination With Bevacizumab With or Without Paclitaxel in Patients With Locally Advanced or Metastatic Solid Tumors | NCT00954642 | Solid Cancers | bevacizumab MNRP1685A paclitaxel | 18 Years - | Genentech, Inc. | |
| A Study of Orally Administered JBI-802, an LSD1/HDAC6 Inhibitor, in Patients With Advanced Solid Tumors | NCT05268666 | Locally Advance... Metastatic Soli... | JBI-802 | 18 Years - | Jubilant Therapeutics Inc. | |
| Lattice Radiotherapy for Dose-Escalated Palliation of Bulky Tumors | NCT06416007 | Cancer Metastatic Canc... Locally Advance... Locally Advance... Locally Advance... | Lattice therapy... | 18 Years - | University of Cincinnati | |
| The Phase I/Phase II Clinical Study of VC004 in Patients With Localized Advanced/Metastatic Solid Tumors | NCT04614740 | Locally Advance... Metastatic Soli... | VC004 | 18 Years - | Jiangsu vcare pharmaceutical technology co., LTD | |
| HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors | NCT03284502 | Locally Advance... Metastatic Soli... | HM95573, cobime... HM95573, cetuxi... HM95573, cobime... HM95573, cetuxi... | 19 Years - | Hanmi Pharmaceutical Company Limited | |
| A Study of TY-2136b in Patients With Advanced Solid Tumors Harboring ALK, ROS1 or NTRK1-3 Alterations | NCT05769075 | Locally Advance... Metastatic Soli... | TY-2136b TY-2136b | 18 Years - | TYK Medicines, Inc | |
| A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer | NCT06184035 | Solid Tumor Metastatic Canc... Unresectable So... Recurrent Solid... Locally Advance... Refractory Canc... | [177Lu]Lu-SN201 | 18 Years - | Spago Nanomedical AB | |
| A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | NCT05118789 | Locally Advance... Metastatic Soli... | NVL-520 | 12 Years - | Nuvalent Inc. | |
| Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors | NCT05169437 | Solid Tumor Breast Tumor Colon Tumor, Ma... Lung Tumor Urologic Cancer Pancreatic Canc... Melanoma Metastatic Canc... Locally Advance... Esophageal Canc... Endometrial Can... Head and Neck C... | Niraparib | 18 Years - | Tempus AI | |
| Advanced Lung Tumor Treated by Osimertinib Plus Anlotinib | NCT04770688 | Non-Small Cell ... Locally Advance... Metastatic Canc... Adenocarcinoma ... | Osimertinib Anlotinib | 18 Years - | Shanghai Chest Hospital | |
| Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients | NCT05002140 | Metastasis Locally Advance... Recurrent Cance... | XRD-0394 Palliative radi... | 18 Years - | XRad Therapeutics Inc | |
| Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors | NCT05275478 | Locally Advance... | TNG908 | 18 Years - | Tango Therapeutics, Inc. | |
| A Retro-/Prospective, Non-interventional, Cohort Study in Adult Patients With Locally Advanced or Metastatic Tumors With a Neurotrophic Tyrosine Receptor Kinase (NTRK) Gene Fusion, Treated With Larotrectinib | NCT04814667 | Solid Tumor, Ad... Locally Advance... Metastatic Canc... | 25 Years - | Centre Leon Berard | ||
| Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors | NCT05732831 | Locally Advance... | TNG462 | 18 Years - | Tango Therapeutics, Inc. | |
| Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation | NCT05919537 | Non-Small Cell ... Pancreatic Canc... Locally Advance... Metastatic Soli... | HMBD-001 Docetaxel Nab-paclitaxel Gemcitabine | 18 Years - | Hummingbird Bioscience | |
| A Study of NVL-520 in Patients With Advanced NSCLC and Other Solid Tumors Harboring ROS1 Rearrangement (ARROS-1) | NCT05118789 | Locally Advance... Metastatic Soli... | NVL-520 | 12 Years - | Nuvalent Inc. | |
| Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients | NCT05002140 | Metastasis Locally Advance... Recurrent Cance... | XRD-0394 Palliative radi... | 18 Years - | XRad Therapeutics Inc | |
| Niraparib in the Treatment of Patients With Advanced PALB2 Mutated Tumors | NCT05169437 | Solid Tumor Breast Tumor Colon Tumor, Ma... Lung Tumor Urologic Cancer Pancreatic Canc... Melanoma Metastatic Canc... Locally Advance... Esophageal Canc... Endometrial Can... Head and Neck C... | Niraparib | 18 Years - | Tempus AI | |
| Double/Triple Combinations of AN2025, AN0025 and Atezolizumab in Advanced Solid Tumors | NCT04975958 | Locally Advance... | AN2025 AN0025 Atezolizumab 12... | 18 Years - | Adlai Nortye Biopharma Co., Ltd. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
